Clinical Trials Browser

Phase 1 × INDUSTRY × IDO-1 inhibitor LY3381916 × Clear all

NCT03335540 2022-09-26

ADVISE

Phase 1 Completed

Advanced Cancer

NCT03343613 2020-06-09

A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

Phase 1 Terminated

BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms